Loss of ADAR1 in macrophages in combination with interferon gamma suppresses tumor growth by remodeling the tumor microenvironment
Journal for ImmunoTherapy of Cancer · 2023-11 · 11 (11) · e007402
DOI: 10.1136/jitc-2023-007402 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 07.11.2023. Verfasst von Weiwei Lin und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathophysiology, College of Basic Medical Science, China Medical University, Shenyang, Liaoning Province, China. Hauptthemen laut MEDLINE: Interferon-gamma, Neoplasms. Die Arbeit wurde bisher 37-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Natural Science Foundation of China, Liaoning Province Xingliao Talent Program, Outstanding Youth Science Foundation in Liaoning Natural Science Foundation Project.
Abstract (Originalsprache)
Background
ADAR1, the major enzyme for RNA editing, has emerged as a tumor-intrinsic key determinant for cancer immunotherapy efficacy through modulating interferon-mediated innate immunity. However, the role of ADAR1 in innate immune cells such as macrophages remains unknown.
Methods
We first analyzed publicly accessible patient-derived single-cell RNA-sequencing and perturbed RNA sequencing data to elucidate the ADAR1 expression and function in macrophages. Subsequently, we evaluated the combined effects of ADAR1 conditional knockout in macrophages and interferon (IFN)-γ treatment on tumor growth in three distinct disease mouse models: LLC for lung cancer, B16-F10 for melanoma, and MC38 for colon cancer. To gain the mechanistic insights, we performed human cytokine arrays to identify differentially secreted cytokines in response to ADAR1 perturbations in THP-1 cells. Furthermore, we examined the effects of ADAR1 loss and IFN-γ treatment on vessel formation through immunohistochemical staining of mouse tumor sections and tube-forming experiments using HUVEC and SVEC4-10 cells. We also assessed the effects on CD8 + T cells using immunofluorescent and immunohistochemical staining and flow cytometry. To explore the translational potential, we examined the consequences of injecting ADAR1-deficient macrophages alongside IFN-γ treatment on tumor growth in LLC-tumor-bearing mice.
Results
Our analysis on public data suggests that ADAR1 loss in macrophages promotes antitumor immunity as in cancer cells. Indeed, ADAR1 loss in macrophages combined with IFN-γ treatment results in tumor regression in diverse disease mouse models. Mechanistically, the loss of ADAR1 in macrophages leads to the differential secretion of key cytokines: it inhibits the translation of CCL20, GDF15, IL-18BP, and TIM-3 by activating PKR/EIF2α signaling but increases the secretion of IFN-γ through transcriptional upregulation and interleukin (IL)-18 due to the 5'UTR uORF. Consequently, decreased CCL20 and GDF15 and increased IFN-γ suppress angiogenesis, while decreased IL-18BP and TIM-3 and increased IL-18 induce antitumor immunity by enhancing cytotoxicity of CD8 + T cells. We further demonstrate that combination therapy of injecting ADAR1-deficient macrophages and IFN-γ effectively suppresses tumors in vivo.
Conclusion
This study provides a comprehensive elucidation of how ADAR1 loss within macrophages contributes to the establishment of an antitumor microenvironment, suggesting the therapeutic potential of targeting ADAR1 beyond the scope of cancer cells.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathophysiology, College of Basic Medical Science, China Medical University, Shenyang, Liaoning Province, China.
- Graduate Program in Quantitative and Computational Biosciences, Baylor College of Medicine, Houston, Texas, USA.
- Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
- Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA hliang1@mdanderson.org xyxu@cmu.edu.cn.
- Department of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
- Department of Pathophysiology, College of Basic Medical Science, China Medical University, Shenyang, Liaoning Province, China hliang1@mdanderson.org xyxu@cmu.edu.cn.
ORCID-Profile: Han Liang
Förderung
- National Natural Science Foundation of China
- Liaoning Province Xingliao Talent Program
- Outstanding Youth Science Foundation in Liaoning Natural Science Foundation Project
- the Barnhart Family Distinguished Professorship from MD Anderson Cancer Center.
- Liaoning BaiQianWan Talents Program
- Shenyang Young and Middle-aged Technological Innovation Talent Support Program
- Shenyang Outstanding Young Scientific and Technological Innovation Talent Support Program
Zitieren
APA
Lin, W., Luo, Y., Wu, J., Zhang, H., Jin, G., Guo, C., Zhou, H., Liang, H., & Xu, X. (2023). Loss of ADAR1 in macrophages in combination with interferon gamma suppresses tumor growth by remodeling the tumor microenvironment. Journal for ImmunoTherapy of Cancer, 11(11), e007402. https://doi.org/10.1136/jitc-2023-007402
Vancouver
Lin W, Luo Y, Wu J, Zhang H, Jin G, Guo C, et al. Loss of ADAR1 in macrophages in combination with interferon gamma suppresses tumor growth by remodeling the tumor microenvironment. Journal for ImmunoTherapy of Cancer. 2023;11(11):e007402. doi:10.1136/jitc-2023-007402
BibTeX
@article{Lin2023,
author = {Lin, Weiwei and Luo, Yikai and Wu, Jie and Zhang, Haowan and Jin, Ge and Guo, Chahua and Zhou, Hang and Liang, Han and Xu, Xiaoyan},
title = {Loss of ADAR1 in macrophages in combination with interferon gamma suppresses tumor growth by remodeling the tumor microenvironment},
journal = {Journal for ImmunoTherapy of Cancer},
year = {2023},
volume = {11},
number = {11},
pages = {e007402},
doi = {10.1136/jitc-2023-007402}
}
EUVIMED